AKERO THERAPEUTICS INC (AKRO) Stock Price & Overview
NASDAQ:AKRO • US00973Y1082
The current stock price of AKRO is 54.65 USD. Today AKRO is up by 0.18%. In the past month the price increased by 1.13%. In the past year, price increased by 89.17%.
AKRO Key Statistics
- Market Cap
- 4.499B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.73
- Dividend Yield
- N/A
AKRO Stock Performance
AKRO Stock Chart
AKRO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AKRO. When comparing the yearly performance of all stocks, AKRO is one of the better performing stocks in the market, outperforming 94.04% of all stocks.
AKRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AKRO. While AKRO has a great health rating, there are worries on its profitability.
AKRO Earnings
AKRO Forecast & Estimates
16 analysts have analysed AKRO and the average price target is 64.26 USD. This implies a price increase of 17.58% is expected in the next year compared to the current price of 54.65.
AKRO Groups
Sector & Classification
AKRO Financial Highlights
Over the last trailing twelve months AKRO reported a non-GAAP Earnings per Share(EPS) of -3.73. The EPS increased by 0.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.12% | ||
| ROE | -30.58% | ||
| Debt/Equity | 0 |
AKRO Ownership
AKRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AKRO
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Company Info
AKERO THERAPEUTICS INC
601 Gateway Boulevard, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Andrew Cheng
Employees: 63
Phone: 16504876488
AKERO THERAPEUTICS INC / AKRO FAQ
Can you describe the business of AKERO THERAPEUTICS INC?
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Can you provide the latest stock price for AKERO THERAPEUTICS INC?
The current stock price of AKRO is 54.65 USD. The price increased by 0.18% in the last trading session.
Does AKRO stock pay dividends?
AKRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of AKRO stock?
AKRO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about AKERO THERAPEUTICS INC (AKRO) stock?
16 analysts have analysed AKRO and the average price target is 64.26 USD. This implies a price increase of 17.58% is expected in the next year compared to the current price of 54.65.
How is the valuation of AKERO THERAPEUTICS INC (AKRO) based on its PE ratio?
AKERO THERAPEUTICS INC (AKRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.73).
Who owns AKERO THERAPEUTICS INC?
You can find the ownership structure of AKERO THERAPEUTICS INC (AKRO) on the Ownership tab.